Penumbra (PEN) Liabilities and Shareholders Equity (2014 - 2026)
Penumbra (PEN) reported Liabilities and Shareholders Equity of $1.9 billion for Q1 2026, up 19.15% year-over-year from $1.6 billion in Q1 2025, and up 3.94% quarter-over-quarter from $1.8 billion in Q4 2025.
Penumbra (PEN) Liabilities and Shareholders Equity (2014 - 2026) Analysis & Trends
Penumbra (PEN) has 13 years of Liabilities and Shareholders Equity data on file, last reported at $1.9 billion in Q1 2026.
- Liabilities and Shareholders Equity for Q1 2026 came in at $1.9 billion, up 19.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.1 billion (up 16.35% YoY), and the FY2025 annual result was $1.8 billion, up 19.13% from the prior year.
- Liabilities and Shareholders Equity advanced to $1.9 billion in Q1 2026 per PEN's latest filing, from $1.8 billion in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $1.9 billion in Q1 2026 and troughed at $1.3 billion in Q1 2022.
- A 5-year average of $1.5 billion and a median of $1.5 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
- The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity surged 54.8% in 2022, then retreated 1.49% in 2024.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.4 billion in 2022, then gained by 13.53% to $1.6 billion in 2023, then fell by 1.49% to $1.5 billion in 2024, then rose by 19.13% to $1.8 billion in 2025, then gained by 3.94% to $1.9 billion in 2026.
- Business Quant data shows PEN's Liabilities and Shareholders Equity at $1.9 billion in Q1 2026, $1.8 billion in Q4 2025, and $1.7 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.92 Bn | 146.27 Bn | 6.27 Bn | 110.43 Bn |
| 2 | Stryker | 119.50 Bn | 116.62 Bn | 3.81 Bn | 46.29 Bn |
| 3 | Medtronic | 102.71 Bn | 94.54 Bn | 5.76 Bn | 91.49 Bn |
| 4 | Boston Scientific | 69.72 Bn | 68.51 Bn | 3.61 Bn | 44.35 Bn |
| 5 | Edwards Lifesciences | 49.24 Bn | 45.57 Bn | 1.29 Bn | 13.32 Bn |
| 6 | GE HealthCare Technologies | 29.74 Bn | 27.67 Bn | 1.98 Bn | 37.13 Bn |
| 7 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 31.92 Bn |
| 8 | Dexcom | 28.96 Bn | 27.84 Bn | 750.30 Mn | 6.63 Bn |
| 9 | Steris | 20.31 Bn | 19.88 Bn | 697.10 Mn | 10.74 Bn |
| 10 | Penumbra | 12.51 Bn | 11.90 Bn | 253.41 Mn | 1.90 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.90 Bn |
| Dec 31, 2025 | 1.83 Bn |
| Sep 30, 2025 | 1.74 Bn |
| Jun 30, 2025 | 1.67 Bn |
| Mar 31, 2025 | 1.59 Bn |
| Dec 31, 2024 | 1.53 Bn |
| Sep 30, 2024 | 1.48 Bn |
| Jun 30, 2024 | 1.53 Bn |
| Mar 31, 2024 | 1.58 Bn |
| Dec 31, 2023 | 1.56 Bn |
| Sep 30, 2023 | 1.47 Bn |
| Jun 30, 2023 | 1.43 Bn |
| Mar 31, 2023 | 1.40 Bn |
| Dec 31, 2022 | 1.37 Bn |
| Sep 30, 2022 | 1.32 Bn |
| Jun 30, 2022 | 1.33 Bn |
| Mar 31, 2022 | 1.30 Bn |
| Dec 31, 2021 | 1.24 Bn |
| Sep 30, 2021 | 973.24 Mn |
| Mar 31, 2021 | 840.82 Mn |